Literature DB >> 20307249

IL-16 effects on A549 lung epithelial cells: dependence on CD9 as an IL-16 receptor?

Santosh Yadav1, Yongli Shi, He Wang.   

Abstract

Interleukin-16 (IL-16) is a pro-inflammatory cytokine released by many types of cells found in the lungs, including normal airway and alveolar epithelial cells. Though a chemotactin for CD4(+) cells and eosinophils, IL-16 also modulates their production of factors that influence inflammatory lung diseases, e.g., asthma and allergic rhinitis. To date, little is known about any potential autocrine-like regulatory effects of IL-16. Using a model human alveolar basal epithelial A549 cell line, the present study sought to assess lung epithelial cell responses to IL-16. Potential induced effects on cell growth/function were assessed using MTT reduction, lactate dehydrogenase release, and 5-bromo-2-deoxyuridine incorporation assays. As IL-16 (at locally high levels) can induce CD4(+) cell death via apoptosis, this potential outcome among the A549 cells was also evaluated using TUNEL and changes in expression of caspase-3 and the pro-apoptotic and anti-apoptotic proteins of Bcl-2 family. The data here indicated that IL-16 inhibited A549 cell growth/function and this was associated with a marked increase in apoptosis characterized by DNA fragmentation, activation of caspase-3, and altered pro-apoptotic protein expression. Since lung epithelial cells lack the CD4 that may bind IL-16, it has been suggested that CD9 may act as an alternate receptor for this cytokine (i.e., an IL-16R). Thus, these studies also sought to determine the extent of CD9 expression on A549 cells and if any/all observed IL-16-induced changes were mediated by CD9. Flow cytometric analyses revealed the cells to be CD9(+)CD4(-). However, neutralization of the purported IL-16R with anti-CD9 antibody could not block the cytotoxic/growth inhibiting effects of IL-16. The only exception appeared to be a mitigation of a chemotactic effect of IL-16; however, studies with an equal amount of non-specific antibody (of same isotype as the anti-CD9) revealed this effect to be artefactual. The neutralization study results thus suggest to us that as-yet undefined pathway(s) exist through which IL-16 may act to exert growth inhibiting/apoptosis-inducing effects on A549 cells, a cell line routinely used as a model for lung epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20307249     DOI: 10.3109/15476911003649346

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  5 in total

1.  Effects of COREXIT dispersants on cytotoxicity parameters in a cultured human bronchial airway cells, BEAS-2B.

Authors:  Yongli Shi; Astrid M Roy-Engel; He Wang
Journal:  J Toxicol Environ Health A       Date:  2013

2.  IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation.

Authors:  Siobhan Smith; Pei Wen Wu; Jane J Seo; Thilini Fernando; Mengyao Jin; Jorge Contreras; Erica N Montano; Joan Ní Gabhann; Kyle Cunningham; Amro Widaa; Eoghan M McCarthy; Eamonn S Molloy; Grainne Kearns; Conor C Murphy; Weiping Kong; Harry Björkbacka; Hardy Kornfeld; Lindsy Forbess; Swamy Venuturupalli; Mariko Ishimori; Daniel Wallace; Michael H Weisman; Caroline A Jefferies
Journal:  JCI Insight       Date:  2018-08-09

3.  Ablation of the CD9 receptor in human lung cancer cells using CRISPR/Cas alters migration to chemoattractants including IL-16.

Authors:  David J Blake; Jonathon D Martiszus; Tia H Lone; Steven D Fenster
Journal:  Cytokine       Date:  2018-06-05       Impact factor: 3.861

Review 4.  CD9, a tetraspanin target for cancer therapy?

Authors:  Aurelio Lorico; Marco Lorico-Rappa; Jana Karbanová; Denis Corbeil; Giuseppe Pizzorno
Journal:  Exp Biol Med (Maywood)       Date:  2021-02-18

5.  Neutrophil-Derived Interleukin 16 in Premetastatic Lungs Promotes Breast Tumor Cell Seeding.

Authors:  Kim Donati; Christelle Sépult; Natacha Rocks; Silvia Blacher; Catherine Gérard; Agnès Noel; Didier Cataldo
Journal:  Cancer Growth Metastasis       Date:  2017-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.